Eckert & Ziegler Focuses on Core Competence and Prepares Split-Off of Clinical Assets
October 20, 2023 at 06:49 pm IST
Share
EQS-Ad-hoc: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Strategic Company Decision
Eckert & Ziegler Focuses on Core Competence and Prepares Split-Off of Clinical Assets
20-Oct-2023 / 15:18 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Berlin, 20 October 2023. The Supervisory Board of Eckert & Ziegler AG (ISIN DE0005659700, SDAX) today has given its approval to the Executive Board to examine and prepare a split-off of up to 100 percent of the shares in the Pentixapharm AG (PTX). In accordance with IFRS 5, the Executive Board will report PTX as a discontinued operation in the 2023 annual financial statements. A separate decision will be taken at a later date on the specific start and the manner of the exit. In accordance with IFRS 5, the Executive Board will report PTX as a discontinued operation in the 2023 annual financial statements. PTX also includes Myelo Therapeutics GmbH.
Given the enormous growth forecast for active pharmaceutical ingredients, which is already reflected in the order intake, Eckert & Ziegler intends to pool its financial resources to expand its global manufacturing capacities. Eckert & Ziegler is thus concentrating on its core competencies in order to further expand its position as a leading supplier of radioisotopes for the production of radiopharmaceuticals.
The forecast for the financial year 2023 remains unchanged.
20-Oct-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com
Language:
English
Company:
Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone:
+49 30 941084-138
Fax:
+49 30 941084-112
E-mail:
karolin.riehle@ezag.de
Internet:
www.ezag.de
ISIN:
DE0005659700
WKN:
565970
Indices:
SDAX,
Listed:
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
Eckert & Ziegler SE is a Germany-based Company, which is a provider of isotope technology for medical, scientific and industrial use with focus on cancer therapy, industrial radiometry and nuclear-medical imaging. The Company operates through three segments: Radiation Therapy, Isotope Products and Radiopharma. The Radiation Therapy segment operates through Eckert & Ziegler BEBIG and produces and distributes medical products for the treatment of cancer using brachytherapy. The Isotope Products segment provides sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration and environmental monitoring sources and solutions, as well as bulk radioisotopes for pharmaceutical, therapeutic and industrial product manufacturers. The Radiopharma segment specializes in molecular imaging and nuclear medicine, and supplies various radiopharmaceuticals, radiochemicals and related equipment.